Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal.  These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.  

The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

"Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Ferriprox is based on an analysis of data from twelve clinical studies in 236 patients. Patients participating in the study did not respond to prior iron chelation therapy.  Ferriprox was considered a successful treatment for patients who experienced at least a 20 percent decrease in serum ferritin, a protein that stores iron in the body for later use. Half of the patients in the study experienced at least a 20 percent decrease in ferritin levels.

The most common side effects seen in patients who received Ferriprox included nausea, vomiting, abdominal and joint pain, urine discoloration (chromaturia), a decrease in the number of white blood cells (neutropenia), and an increase in
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... JOSE, Calif. , May 26, 2015  SI-BONE, ... of the iFuse Implant System, a minimally invasive surgical ... the sacroiliac (SI) joint, announced today that Laura ... officer effective immediately.   Ms. Francis joins the executive management ... and private companies in executive leadership positions.  ...
(Date:5/26/2015)... MARLBOROUGH, Mass. , May 26, 2015 ... ), a biotechnology company focused on discovering ... areas of dermatology and ophthalmology, today announced that ... Geert Cauwenbergh , will present at the ... June 4, 2015 at 11:30 a.m. EDT. ...
(Date:5/26/2015)... , May 26, 2015  InMed Pharmaceuticals ... that it has filed a provisional patent application ... ("USPTO") relating to the treatment of Epidermolysis Bullosa ... compounds developed by InMed. Dr. ... Officer, commented, "We are excited to file our ...
Breaking Medicine Technology:SI-BONE, Inc. Appoints Laura Francis Chief Financial Officer and Closes Additional Round of Growth Capital 2SI-BONE, Inc. Appoints Laura Francis Chief Financial Officer and Closes Additional Round of Growth Capital 3SI-BONE, Inc. Appoints Laura Francis Chief Financial Officer and Closes Additional Round of Growth Capital 4RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 2RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 4InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 2InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 3
... Medical Inc. (TMI),announced today that it has been ... commercialize in Europe the Antares(TM) Coronary,Stent System, a ... use,at or near coronary bifurcations., Representing the ... potential use in a quarter of the 2.2 ...
... Line Clinical Results Expected in November 2008, BOTHELL, ... ) announced today the completion of patient enrollment and ... evaluate the safety and,efficacy of its formulation of 12-hour ... expects to report top-line,results from this pivotal trial in ...
Cached Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3
(Date:5/26/2015)... NC (PRWEB) May 26, 2015 ... compliance solutions for the health and human services market, ... to meet demand. After strong attendance and participation in ... groups, and give their annual user conference an exciting ... Relias customers to come together and discuss best practices, ...
(Date:5/26/2015)... MD (PRWEB) May 26, 2015 ... marijuana. According to an article published by ... synthetic marijuana (dubbed K2, Spice, and black mamba) ... composition of these synthetic substances make it nearly ... confirm patients’ use of the substance due to ...
(Date:5/26/2015)... 26, 2015 Pasadena porcelain veneers ... dental cleanings with cosmetic treatments. Cosmetic dentistry is becoming ... Dentistry , “We are committed to providing you with ... outstanding customer service and a smile of a lifetime ... your smiles but to change your life,” explains Dr. ...
(Date:5/26/2015)... Indosoft, Inc ., developer of ... DMi Partners contact center to Q-Suite 5.8 ... Indosoft's contact center ACD system to drop Asterisk 1.4 ... such trunk features as diversion headers, added Lyra support ... upgrades to warm transfers to improve information ...
(Date:5/26/2015)... May 26, 2015 National Prevention Week ... year. It is supported by the Substance Abuse ... raising public awareness of, and action about, substance abuse ... organizations and coalitions are encouraged to join in promoting ... and related issues, and in building community partnerships. , ...
Breaking Medicine News(10 mins):Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 2Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 3Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3
... ... Speaks at Gladys B. Jacobs Manor, in North Central Philadelphia , ... Philadelphia, PA (Vocus) October 28, 2009 ... Latina ever appointed to that position, recently spoke at the Original Richard Allen Committee’s ...
... /PRNewswire/ - LPBP Inc. (the "Company") announces a ... related to the per share dividend payable on ... dividend on the Class B Non-Voting shares should ... A Common shares of $0.0099 per share remains ...
... Oct. 28 In response to rising suicide and ... dedicated to supporting marriages and families, will present its ... to military couples in Milwaukee from Nov. 6 - 8 ... Weekend to Remember is a marriage getaway aimed ...
... California religious and community leaders, who have witnessed first ... well as the homeless, sick and mentally ill, gathered ... legalizing marijuana sales and use in California. , ... numerous faiths and religious denominations, were joined by community ...
... in tissue damage caused by smoking , WEDNESDAY, Oct. ... therapy for injured lungs that were previously rejected for ... transplant, researchers say. , Successful transplants require healthy lungs, ... highly inflamed and only mildly functional, which means many ...
... 28 If we get a boo-boo, we might know to ... kiss it and make it all better. But, what if ... us who aren,t prepared for dental emergencies can quickly get back ... Company at: , http://inr.mediaseed.tv/oneClip_C/?feed=Ss8P5Rb1iQulYDAELUR0M_kpwKp_6YSM , Medialink ...
Cached Medicine News:Health News:Head of PA Department of Aging Speaks at the Richard Allen Committee's 17th Annual Senior Citizen's Event 2Health News:FamilyLife Supports Military Marriages in Milwaukee 2Health News:Faith-Based Leaders and Community Activists Converge on State Capitol to Oppose Legalized Marijuana 2Health News:Faith-Based Leaders and Community Activists Converge on State Capitol to Oppose Legalized Marijuana 3Health News:Repairing Injured Lungs May Boost Organ Donations 2
... Cell-Chex is a spinal and body fluid ... When stained in the same manner as ... can be differentiated. The two-level control is ... white blood cell differential, as well as ...
... is a gene expression ... the risk of metastasis ... It is based on ... the Netherlands Cancer Institute ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: